Home›Companies›Healthcare›Contraline

Contraline, Inc.

Develops investigational contraceptive gel and implants for men.

Updated Nov 10, 2026·Latest SEC filing Jun 10, 2026·Suggest an edit

About Contraline

Contraline is a private company based in Charlottesville, Virginia. It has reported $63,030,410 raised in two offerings on Form D since April 2022. Its chief executive is Kevin Eisenfrats.

Funding Rounds (SEC Form D)

First saleFiled with SECAmount soldInvestorsAvg. checkTermsFiling
May 29, 2026Jun 10, 2026$55,804,741of $115.9M target77$724KEquityRule 506(b)Form D ↗
Mar 2, 2021Apr 5, 2022$7,225,669of $7.5M target22$328KOptions, Securities on exerciseRule 506(b)Form D ↗
Total, two offerings$63,030,410

First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.

Leadership Team

Executive officers and directors listed on Contraline's Form D filed Jun 10, 2026.

Kevin Eisenfrats
Kevin Eisenfrats
Co-Founder and CEO, director
ME
Gurdane Bhutani
Gurdane Bhutani
Managing Partner and director
Also a director at Ancilia Bio and Junction Health.

Earlier filings also listed Tom Thorpe (director, last listed Apr 2022) and Michael King (director, last listed Apr 2022).

Sources

  1. SECContraline, Inc. filing history
  2. CompanyContraline contact
  3. CompanyContraline team